Relevance of New Conduction Disorders After Implantation of the ACURATE Neo Transcatheter Heart Valve in the Aortic Valve Position
Section snippets
Methods
Between June 2015 and June 2019, consecutive patients undergoing TAVR with the ACURATE neo or ACURATE neo 2 THV at the Heart Center Lucerne were enrolled in the prospective SwissTAVI registry. Data were collected throughout the initial hospital stay and follow-ups were conducted at 30 days and 1 year. The study complies with the declaration of Helsinki. Prospective data acquisition was approved by the local ethic committee. All patients provided written informed consent for the TAVR procedure,
Results
A total of 229 consecutive patients who underwent TAVR with ACURATE neo were enrolled. Of those, 26 patients with a pre-existing LBBB or PPM were excluded from the current analyses. Mean age of the study cohort was 82 ± 6 years and 128 (63%) were women. ECG at discharge showed a new LBBB in 22 (11%) patients and 6 (3%) patients had received a new PPM. These patients were compared with the remaining 175 (86%) patients with an unchanged ECG. Baseline characteristics and procedural details of the
Discussion
Evaluating data from a prospective registry, we assessed the impact of TAVR with the ACURATE neo valve on occurrence of CDs. We found (1) implantation of the ACURATE neo resulted in remarkably low rates of new CDs; (2) new CDs prolonged the median duration of hospitalization by 2 days; (3) patients with new CDs had a significantly lower LVEF at 1-year follow-up; and (4) patients without new CDs had excellent short- and midterm outcomes with a remarkably high 1-year survival rate of 95%.
Authorship Contribution
Conception and design or analysis and interpretation of data, or both: MB, ST. Drafting of the manuscript or revising it critically for important intellectual content: MB, MW, FM, MBo, BB, FC, RK, ST. Final approval of the manuscript submitted: all authors.
Disclosure
ST is a consultant and proctor for Boston Scientific and New Valve Technology, and has received institutional research grants from Boston Scientific and Fumedica AG. The other authors have no conflicts of interest to declare.
References (17)
- et al.
Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry
JACC Cardiovasc Interv
(2015) - et al.
Mortality and heart failure hospitalization in patients with conduction abnormalities after transcatheter aortic valve replacement
JACC Cardiovasc Interv
(2019) - et al.
The SAVI-TF registry: 1-year outcomes of the European Post-Market registry using the ACURATE neo transcatheter heart valve under real-world conditions in 1,000 patients
JACC Cardiovasc Interv
(2018) - et al.
Correlation of device landing zone calcification and acute procedural success in patients undergoing transcatheter aortic valve implantations with the self-expanding CoreValve prosthesis
JACC Cardiovasc Interv
(2010) - et al.
Changes in the pacemaker rate after transition from edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height
JACC Cardiovasc Interv
(2016) - et al.
Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis
JACC Cardiovasc Interv
(2014) - et al.
The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring
JACC Cardiovasc Interv
(2016) - et al.
Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve((R)) devices: results from the FRANCE 2 Registry
Catheter Cardiovasc Interv
(2015)
Cited by (0)
Funding: There was no funding for this study.